Find comprehensive information on metastatic breast cancer, including clinical documentation, medical coding (ICD-10 C50.9, C79.81), staging (TNM), treatment options, and healthcare resources. Learn about secondary breast cancer, distant recurrence, and advanced breast cancer management. Explore symptoms, diagnosis, and palliative care for metastatic breast cancer patients. This resource provides essential information for healthcare professionals, patients, and caregivers seeking guidance on metastatic breast cancer.
Also known as
Malignant neoplasm of breast
Metastatic breast cancer, unspecified site
Secondary malignant neoplasms
Metastasis to specified sites, including potential breast cancer spread
Secondary malignant neoplasm of other specified sites
Metastatic breast cancer to other specified sites
Malignant (primary) neoplasm, unspecified
Used when the primary site is unknown, but malignancy is present, potentially breast
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the breast cancer primary?
Yes
Do NOT code as metastatic. Code the primary breast cancer.
No
Is the site of metastasis known?
When to use each related code
| Description |
|---|
| Metastatic Breast Cancer |
| Breast Cancer, Invasive |
| Breast Cancer, In Situ |
Incorrect coding of right, left, or unspecified breast, impacting staging and treatment data accuracy. Relevant for medical coding, CDI, and healthcare compliance.
Missing documentation of metastatic site details (bone, liver, etc.) leads to inaccurate coding and underreporting severity. Crucial for medical coding, CDI, and compliance.
Incorrect primary/secondary sequence of breast cancer and metastatic disease codes affects reimbursement and quality reporting. Key for medical coding, CDI, and healthcare compliance.
Q: What are the most effective current treatment strategies for managing hormone receptor-positive, HER2-negative metastatic breast cancer in postmenopausal women?
A: Hormone receptor-positive (HR+), HER2-negative metastatic breast cancer in postmenopausal women is commonly treated with endocrine therapy as the first line of treatment. Current guidelines recommend aromatase inhibitors like anastrozole, letrozole, or exemestane as initial therapy. Fulvestrant, a selective estrogen receptor degrader (SERD), can be utilized in cases of disease progression on aromatase inhibitors or as initial therapy in certain situations. CDK4/6 inhibitors, such as palbociclib, ribociclib, and abemaciclib, are also frequently used in combination with endocrine therapy to improve progression-free survival. The specific choice of endocrine therapy and CDK4/6 inhibitor depends on individual patient factors, prior treatments, and disease characteristics. Explore how different combinations of endocrine therapy and targeted agents can optimize treatment outcomes in individual patients. Consider implementing strategies for managing treatment-related side effects to improve patient adherence and quality of life. Learn more about the latest clinical trial data regarding sequencing and duration of these treatments.
Q: How can I differentiate between the clinical presentations of locally advanced breast cancer and metastatic breast cancer to ensure accurate staging and treatment planning?
A: Differentiating between locally advanced breast cancer (LABC) and metastatic breast cancer (MBC) hinges on the extent of disease spread. LABC involves extensive involvement of the breast and surrounding tissues, such as skin or chest wall, and/or significant regional lymph node involvement, but without distant metastases. MBC, on the other hand, is defined by the presence of cancer cells in distant organs like bones, lungs, liver, or brain. Careful clinical examination, including assessment of the primary tumor, regional lymph nodes, and a thorough evaluation for signs and symptoms suggestive of distant metastasis, are crucial. Imaging studies, such as CT scans, bone scans, and PET scans, play a critical role in confirming the presence or absence of distant metastases. Biopsy of suspicious lesions is essential for definitive diagnosis of metastatic disease. Accurate staging is paramount for guiding appropriate treatment decisions. Consider implementing multidisciplinary tumor board discussions to ensure comprehensive evaluation and personalized treatment planning for patients with LABC or MBC. Learn more about the role of advanced imaging techniques in detecting and characterizing metastatic lesions.
Patient presents with metastatic breast cancer (MBC), confirmed by biopsy and imaging studies. The primary breast cancer diagnosis was invasive ductal carcinoma, originally diagnosed in [Month, Year], with estrogen receptor (ER) [positive/negative], progesterone receptor (PR) [positive/negative], and human epidermal growth factor receptor 2 (HER2) [positive/negative] status. Current metastatic sites include [List sites, e.g., bone, lung, liver]. Patient reports symptoms of [List symptoms, e.g., bone pain, fatigue, shortness of breath]. Performance status is documented as Eastern Cooperative Oncology Group (ECOG) [0-5]. Treatment plan includes [Specify treatment, e.g., chemotherapy with [drug regimen], hormone therapy with [drug regimen], targeted therapy with [drug regimen], radiation therapy to [site], palliative care]. Discussed treatment options, risks, and benefits with the patient. Patient demonstrates understanding and consents to the proposed plan. Referrals made to [List referrals, e.g., oncology, pain management, social work]. Scheduled follow-up appointment in [Timeframe]. ICD-10 code C50.9 (Malignant neoplasm of breast, unspecified) with appropriate site-specific codes for metastases will be utilized for billing and coding purposes. Prognosis discussed with patient and family. Patient education provided regarding disease management, symptom control, and available support services. Patient with a history of [Stage] [ER/PR/HER2 status] breast cancer, originally diagnosed in [Month, Year], now presents with clinical and radiographic evidence of metastatic disease. Metastatic workup, including [Specify imaging modalities, e.g., CT scan, bone scan, PET scan], confirms metastatic involvement of [List sites]. Patient's symptoms include [List symptoms]. Patient reports a performance status consistent with ECOG [0-5]. Considering patient's medical history, current performance status, and molecular subtype, the treatment plan includes [Specify treatment, e.g., first-line, second-line, or subsequent-line therapy with specific regimen]. Potential treatment-related adverse effects, including [List potential side effects], were discussed with the patient. Genetic testing for [Specify genes, e.g., BRCA1/2] is [recommended/not recommended/already performed and results are [positive/negative]]. Patient agrees with the proposed treatment plan and understands the potential risks and benefits. Referral to [List referrals, e.g., oncology nutrition, physical therapy] has been made. Follow-up appointment scheduled in [Timeframe]. ICD-10 code C50.9 will be used, along with site-specific metastasis codes, for accurate medical billing and coding. Advanced care planning and palliative care options were also discussed. Patient will continue to be monitored closely for treatment response and disease progression.